Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Predictive Markers in GHD and TS Children Treated With SAIZEN®

This study has been completed.
Sponsor:
Information provided by:
Merck KGaA
ClinicalTrials.gov Identifier:
NCT00256126
First received: November 18, 2005
Last updated: March 26, 2014
Last verified: March 2014